Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells

Cancer Research

Volumn 71, Issue 12, 2011, Pages 4236-4246

  Damelin, Marc ^a   Geles, Kenneth G ^a   Follettie, Maximillian T ^a   Yuan, Ping ^b   Baxter, Michelle ^a   Golas, Jonathon ^a   DiJoseph, John F ^a   Karnoub, Maha ^a   Huang, Shuguang ^a   Diesl, Veronica ^a   Behrens, Carmen ^b   Choe, Sung E ^a   Rios, Carol ^a   Gruzas, Janet ^a   Sridharan, Latha ^a   Dougher, Maureen ^a   Kunz, Arthur ^a   Hamann, Philip R ^a   Evans, Deborah ^a   Armellino, Douglas ^a   Khandke, Kiran ^a   Marquette, Kimberly ^a   Tchistiakova, Lioudmila ^a   Boghaert, Erwin R ^a   Abraham, Robert T ^a   Wistuba, Ignacio I ^b   Zhou, Bin Bing S ^a   more..

^a PFIZER INC   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALICHEAMICIN; CAMPTOTHECIN; CD24 ANTIGEN; CD44V ANTIGEN; CISPLATIN; FLUOROURACIL; INOTUZUMAB OZOGAMICIN; MEMBRANE PROTEIN; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; PROTEIN 5T4; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; CANCER SURVIVAL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL SUBPOPULATION; COLONY FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE ACTIVATED CELL SORTING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR CELL; TUMOR REGRESSION;

ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; IMMUNOTOXINS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASTIC STEM CELLS;

EID: 79958819359     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3919     Document Type: Article

References (39)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94. (Pubitemid 351720831)
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
3. Sica G, Yoshizawa A, Sima CS, Azzoli CG, Downey RJ, Rusch VW, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010;34:1155-62.
4. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007;2:327-43. (Pubitemid 47181718)
5. Sun Z, Aubry MC, Deschamps C, Marks RS, Okuno SH, Williams BA, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg 2006;131:1014-20.
6. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007;23:675-99.
7. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11. (Pubitemid 33041634)
8. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-23.
9. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
10. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005;5:675-88. (Pubitemid 41486361)
11. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391-403. (Pubitemid 43668737)
12. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-7.
13. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 1988;57:239-46. (Pubitemid 18096328)
14. Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer 1996;68:84-92. (Pubitemid 26354583)
15. Eastham AM, Spencer H, Soncin F, Ritson S, Merry CL, Stern PL, et al. Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res 2007;67:11254-62. (Pubitemid 350248551)
16. Southgate TD, McGinn OJ, Castro FV, Rutkowski AJ, Al-Muftah M, Marinov G, et al. CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic stem cells. PLOS One 2010;5:e9982.
17. Awan A, Lucic MR, Shaw DM, Sheppard F, Westwater C, Lyons SA, et al. 5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasis. Biochem Biophys Res Commun 2002;290:1030-6. (Pubitemid 34687466)
18. Barrow KM, Ward CM, Rutter J, Ali S, Stern PL. Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia. Dev Dyn 2005;233:1535-45. (Pubitemid 40995151)
19. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-8.
20. Reynolds SD, Malkinson AM. Clara cell: progenitor for the bronchiolar epithelium. Int J Biochem Cell Biol 2010;42:1-4.
21. Vaughan MB, Ramirez RD, Wright WE, Minna JD, Shay JW. A three-dimensional model of differentiation of immortalized human bronchial epithelial cells. Differentiation 2006;74:141-8.
22. Boghaert ER, Sridharan L, Khandke KM, Armellino D, Ryan MG, Myers K, et al. The oncofetal protein, 5T4, is a suitable target for antibodyguided anti-cancer chemotherapy with calicheamicin. Int J Oncol 2008;32:221-34. (Pubitemid 351176081)
23. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002;13:47-58. (Pubitemid 34119634)
24. Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 2002;13:40-6. (Pubitemid 34119633)
25. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004;103:1807-14. (Pubitemid 38268977)
26. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15. (Pubitemid 351636299)
27. Naganuma H, Kono K, Mori Y, Takayoshi S, Stern PL, Tasaka K, et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res 2002;22:1033-8. (Pubitemid 34836147)
28. Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, Stern PL. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 1994;69:899-902. (Pubitemid 24140671)
29. Wrigley E, McGown AT, Rennison J, Swindell R, Crowther D, Starzynska T, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer 1995;5:269-74.
30. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009;106:16281-6.
31. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-14. (Pubitemid 351267301)
32. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell populations. Cell 2010;141:69-80.
33. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 2010;126:950-8.
34. Li L, Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 2010;327:542-5.
35. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
36. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010;18:510-23.
37. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008;68:6043-8.
38. De Luca A, Normanno N. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. Curr Drug Targets 2010;11:851-64.
39. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010;120:485-97.